BriaCell Therapeutics Corp. (BCTX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, BriaCell Therapeutics reported revenue of $0. Net income was -$26.3M, or -$62.19 per diluted share. Operating activities generated -$28.2M of cash, leaving -$28.6M of free cash flow. At fiscal year end, BriaCell Therapeutics held $21.6M in total assets against $4.3M in total liabilities, including $10.5M of cash and equivalents.
Open the full interactive BriaCell Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
BriaCell Therapeutics Key Stats
| Share Price | $3.71 |
|---|---|
| Market Cap | $26.9M |
| 52-Week Range | $2.74 – $13.79 |
| Shares Outstanding | 7.3 million (basic, 2026 Q3) |
BriaCell Therapeutics Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$15.3M | -$23.3M | -$33.3M | -$27.2M |
| Pre-Tax Income | -$26.8M | -$20.3M | $4.9M | $26.6M |
| Income Tax | — | — | $9.7M | $52.9M |
| Net Income | -$26.8M | -$20.3M | -$4.8M | -$26.3M |
| Diluted EPS | — | -$13.00 | -$2.90 | -$62.19 |
BriaCell Therapeutics Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.1M | -$8.2M | -$7.2M | -$7.2M |
| Diluted EPS | -$19.12 | -$4.35 | -$2.58 | -$0.99 |
BriaCell Therapeutics Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $41.0M | $21.3M | $862,089 | $10.5M |
| Current Assets | $42.3M | $26.9M | $3.7M | $19.9M |
| Total Assets | $42.6M | $27.2M | $5.9M | $21.6M |
| Current Liabilities | $941,087 | $1.8M | $7.5M | $4.0M |
| Total Liabilities | $32.2M | $30.9M | $8.6M | $4.3M |
| Shareholders' Equity | $10.3M | -$3.8M | -$2.7M | $17.3M |
BriaCell Therapeutics Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$12.5M | -$23.7M | -$24.1M | -$28.2M |
| Cash From Investing | — | — | -$681,801 | -$7.6M |
| Cash From Financing | -$3.7M | $4.0M | $4.4M | $45.4M |
| Free Cash Flow | — | — | -$24.6M | -$28.6M |
Figures from BriaCell Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BriaCell Therapeutics financials page for every line item.
BriaCell Therapeutics Company Profile
| Ticker | BCTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | West Vancouver, British Columbia, Canada |
| Fiscal Year End | July 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001610820 |
Frequently Asked Questions
What was BriaCell Therapeutics' revenue in fiscal 2025?
BriaCell Therapeutics (BCTX) reported revenue of $0 for fiscal 2025.
What is BriaCell Therapeutics' annual revenue history?
BriaCell Therapeutics' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was BriaCell Therapeutics' net income in fiscal 2025?
BriaCell Therapeutics reported net income of -$26.3M for fiscal 2025.
What was BriaCell Therapeutics' earnings per share (EPS) in fiscal 2025?
BriaCell Therapeutics' diluted EPS was -$62.19 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did BriaCell Therapeutics generate in fiscal 2025?
BriaCell Therapeutics generated -$28.6M of free cash flow in fiscal 2025.
What was BriaCell Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q3), BriaCell Therapeutics reported revenue of $0.
How many shares of BriaCell Therapeutics are outstanding?
BriaCell Therapeutics reported a weighted average of 7.3 million basic shares outstanding in 2026 Q3.
What is BriaCell Therapeutics' market cap?
Based on its latest closing price, BriaCell Therapeutics (BCTX) has a market capitalization of about $26.9M.
When does BriaCell Therapeutics' fiscal year end?
BriaCell Therapeutics' fiscal year end, as registered with the SEC, is July 31.
Where is BriaCell Therapeutics headquartered?
BriaCell Therapeutics lists its business address in West Vancouver, British Columbia, Canada in its SEC filings.